PAION AG
- WKN: A0B65S
- ISIN: DE000A0B65S3
- Land: Deutschland
Nachricht vom 19.11.2020 | 22:44
PAION REPORTS POSITIVE REMIMAZOLAM TOPLINE DATA IN EU PHASE III TRIAL IN GENERAL ANESTHESIA
PAION AG / Key word(s): Research Update
PAION REPORTS POSITIVE REMIMAZOLAM TOPLINE DATA IN EU PHASE III TRIAL IN GENERAL ANESTHESIA
- Primary endpoint met: remimazolam demonstrated non-inferiority to propofol for anesthetic effect - Key secondary endpoint met: remimazolam demonstrated superior hemodynamic stability compared to propofol - EU Phase III program completed; data to serve as basis for MAA submission in general anesthesia Aachen (Germany), 19 November 2020 - The Specialty Pharma Company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange Prime Standard: PA8) today announces positive topline data from the pivotal remimazolam EU Phase III trial in general anesthesia. In the trial with 424 patients, remimazolam met both the primary and key secondary endpoints. The randomized, single-blind, propofol-controlled, confirmatory Phase III trial enrolled 424 ASA III/IV patients (American Society of Anesthesiologists classification III to IV) undergoing planned surgery at more than 20 European sites. The primary objective of the trial was to demonstrate non-inferiority of remimazolam compared to propofol for the induction and maintenance of general anesthesia during elective surgery. The primary efficacy endpoint was defined as the anesthetic effect of remimazolam and propofol assessed as a percentage of time of a Narcotrend (NCT) index below 60 (depth of anesthesia) during the maintenance phase of general anesthesia. In the final analysis, non-inferiority was demonstrated with an NCT index below 60 with 95.7% (n=235) of the time with remimazolam and 99.1% (n=92) with propofol at a significance level of p=0.0001. The key secondary objective was to show improved hemodynamic stability compared to propofol. Hemodynamic stability is measured by avoidance of intraoperative drop in mean arterial blood pressure (MAP) between start of anesthesia and 15 minutes after the first skin incision, as well as usage of vasopressors. Although adjustments in the statistical testing were required based on the nature of the obtained data, a statistically significant superior hemodynamic stability of remimazolam compared to propofol could be shown with a number of hemodynamic events per patient of 62.62 ± 39.46 (n=270) with remimazolam and 71.03 ± 41.12 (n=95) with propofol at a significance level of p=0.0151. End of inside information Information and Explanation of the Issuer to this News: About PAION In Europe, PAION is seeking approval of remimazolam for general anesthesia and for procedural sedation. PAION submitted a Marketing Authorization Application (MAA) for procedural sedation in November 2019. PAION's mission is to be a leading specialty pharmaceutical company in the fields of anesthesia and critical care by bringing novel products to market to benefit patients, doctors & other stakeholders in healthcare. PAION is headquartered in Aachen (Germany) with an additional site in Cambridge (United Kingdom). Contact Disclaimer:
19-Nov-2020 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. |
Language: | English |
Company: | PAION AG |
Martinstr. 10-12 | |
52062 Aachen | |
Germany | |
Phone: | +49 (0)241-4453-0 |
Fax: | +49 (0)241-4453-100 |
E-mail: | info@paion.com |
Internet: | www.paion.com |
ISIN: | DE000A0B65S3 |
WKN: | A0B65S |
Listed: | Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart, Tradegate Exchange |
EQS News ID: | 1149475 |
End of Announcement | DGAP News Service |
Interaktiv
Weitere News
-
20.04.21 15:05
PAION AG: Bekanntmachung der Einberufung zur H ... -
09.04.21 20:00
PAION AG: Release according to Article 41 of t ... -
07.04.21 12:16
PAION AG ANNOUNCES SUCCESSFUL COMPLETION OF CA ... -
07.04.21 09:00
PAION ANNOUNCES PRODUCT LAUNCH OF BYFAVO (REMI ... -
30.03.21 17:01
PAION AG REPORTS ON SUCCESSFUL FISCAL Y ...
Event im Fokus

Termine 2021
10. Juni 2021:Fachkonferenz Immobilien
14./15. Juli 2021: Fachkonferenzen Beteiligungsgesellschaften & Consumer/Leisure
13./14. Oktober 2021: Fachkonferenzen Finanzdienstleistungen/Technologie
10./11. November 2021: Fachkonferenzen Software/IT & Branchenmix
„Je nach aktueller Covid-19 Situation und den bestehenden Vorschriften für Versammlungen entscheidet sich ca. 5 Wochen vor dem Termin, in welcher Form die Konferenzen stattfinden.“
GBC-Fokusbox

11 Perlen im „GBC Fonds Champions 2021“
Im Rahmen der aktuellen Studie „GBC Fonds Champions 2021“ haben wir elf versteckte Fondsperlen mit dem Kriterium einer Mindestbewertung von 4 von 5 GBC-Falken ausgewählt. Auch tragen wir dem gesteigerten Investoreninteresse nach nachhaltigen Investments Rechnung und haben drei nachhaltige Fonds ausgewählt. Übrigens, die Fonds aus unserer letzten Ausgabe haben im Schnitt eine Performance von plus 31,8 % erreicht.
Der AKTIONÄR News

22. April 22:37 Intel mit soliden Quartalszahlen trotz Gewinnrückgang
22. April 20:40 Snap: Überzeugende Quartalsergebnisse – so kann es weitergehen
22. April 20:30 Schlussglocke: Biden-Pläne grätschen Dow und Nasdaq weg
22. April 19:21 Facebook: Jetzt soll die Cash-Maschine Instagram richtig laufen
22. April 18:33 Tesla: Verbraucherschützer tricksen Autopilot aus – Aktie auf Talfahrt
News im Fokus

Engagement für Vielfalt und Inklusion: Delivery Hero gründet Diversity & Inclusion Advisory Board
22. April 2021, 08:00